FDMT – 4d molecular therapeutics, inc. (US:NASDAQ)
Stock Stats
News
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) is now covered by analysts at Morgan Stanley. They set an "underweight" rating and a $8.00 price target on the stock.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $39.00 price target on the stock.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $36.00 price target on the stock.
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) had its price target lowered by analysts at Royal Bank of Canada from $40.00 to $39.00. They now have an "outperform" rating on the stock.
4DMT to Participate in Upcoming Investor Conferences and Ophthalmology Innovation Summit XIV
Form SC 13G/A 4D Molecular Therapeutic Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SC 13G/A 4D Molecular Therapeutic Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SC 13G/A 4D Molecular Therapeutic Filed by: VIKING GLOBAL INVESTORS LP
Form SC 13G/A 4D Molecular Therapeutic Filed by: JANUS HENDERSON GROUP PLC
Form SC 13G/A 4D Molecular Therapeutic Filed by: Deep Track Capital, LP
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.